Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Bunda, Severa ^a   Burrell, Kelly ^b   Heir, Pardeep ^a   Zeng, Lifan ^c   Alamsahebpour, Amir ^b   Kano, Yoshihito ^a   Raught, Brian ^d   Zhang, Zhong Yin ^c   Zadeh, Gelareh ^b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c INDIANA UNIVERSITY   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; PROTEIN P21;

CHEMICAL BINDING; ENZYME ACTIVITY; GENE EXPRESSION; HYDROLYSIS; INHIBITION; PHOSPHATASE; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER GRADING; CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; EMBRYO; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NEWBORN; NOD SCID MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL LINE; ENZYMOLOGY; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE;

MUS;

ANIMALS; CARCINOGENESIS; CELL LINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; ONCOGENE PROTEIN P21(RAS); PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84948674328     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9859     Document Type: Article

References (63)

1. Harvey, J. J. An unidentified virus which causes the rapid production of tumours in mice. Nature 204, 1104-1105 (1964).
2. Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311-335 (1967).
3. Cox, A. D. & Der, C. J. Ras history: The saga continues. Small GTPases 1, 2-27 (2010).
4. Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779-827 (1987).
5. Wennerberg, K., Rossman, K. L. & Der, C. J. The Ras superfamily at a glance. J. Cell Sci. 118, 843-846 (2005).
6. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J. & Der, C. J. Increasing complexity of Ras signaling. Oncogene 17, 1395-1413 (1998).
7. Lowy, D. R. & Willumsen, B. M. Function and regulation of ras. Annu. Rev. Biochem. 62, 851-891 (1993).
8. Milburn, M. V., et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939-945 (1990).
9. Scheffzek, K., et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338 (1997).
10. Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J. & McCormick, F. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240, 518-521 (1988).
11. Mattingly, R. R. Activated Ras as a therapeutic target: constraints on directly targeting ras isoforms and wild-type versus mutated proteins. ISRN Oncol. 2013, 536529 (2013).
12. DeClue, J. E., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265-273 (1992).
13. Schubbert, S., et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106, 311-317 (2005).
14. Clark, G. J. & Der, C. J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 35, 133-144 (1995).
15. Guha, A., Feldkamp, M. M., Lau, N., Boss, G. & Pawson, A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15, 2755-2765 (1997).
16. Louis, D. N., Holland, E. C. & Cairncross, J. G. Glioma classification: a molecular reappraisal. Am. J. Pathol. 159, 779-786 (2001).
17. Kleihues, P. & Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1, 44-51 (1999).
18. Holland, E. C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2, 120-129 (2001).
19. Jiang, B. H., Aoki, M., Zheng, J. Z., Li, J. & Vogt, P. K. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc. Natl Acad. Sci. USA 96, 2077-2081 (1999).
20. Scott, L. M., et al. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg. Med. Chem. Lett. 21, 730-733 (2011).
21. Bunda, S., et al. Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. Proc. Natl Acad. Sci. USA 111, E3785-E3794 (2014).
22. Scott, L. M., Lawrence, H. R., Sebti, S. M., Lawrence, N. J. & Wu, J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des. 16, 1843-1862 (2010).
23. Zhang, X., et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53, 2482-2493 (2010).
24. Sha, F., et al. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc. Natl Acad. Sci. USA 110, 14924-14929 (2013).
25. Ding, H., et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 61, 3826-3836 (2001).
26. Mohi, M. G., et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7, 179-191 (2005).
27. Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. & Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100, 1786-1793 (2009).
28. Chan, R. J. & Feng, G. S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867 (2007).
29. Dance, M., Montagner, A., Salles, J. P., Yart, A. & Raynal, P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell. Signal. 20, 453-459 (2008).
30. Ren, L., et al. Substrate specificity of protein tyrosine phosphatases 1B, RPTPalpha, SHP-1, and SHP-2. Biochemistry 50, 2339-2356 (2011).
31. Huang, H., et al. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev. 26, 1587-1601 (2012).
32. Charpantier, E., et al. Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J. Neurosci. 25, 9836-9849 (2005).
33. Huang, W. Q., et al. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Curr. Cancer Drug Targets 14, 567-588 (2014).
34. Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L. & Wu, J. Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor. J. Biol. Chem. 275, 13842-13848 (2000).
35. Egan, S. E., et al. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363, 45-51 (1993).
36. Montagner, A., et al. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280, 5350-5360 (2005).
37. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K. & Nishida, E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J. Biol. Chem. 279, 22992-22995 (2004).
38. Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A. & Swain, J. L. Inhibition of angiogenesis by a mouse sprouty protein. J. Biol. Chem. 276, 4128-4133 (2001).
39. Li, X., Wheldon, L. & Heath, J. K. Sprouty: a controversial role in receptor tyrosine kinase signalling pathways. Biochem. Soc. Trans. 31, 1445-1446 (2003).
40. Zhang, S. Q., et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13, 341-355 (2004).
41. Peyssonnaux, C. & Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93, 53-62 (2001).
42. Tartaglia, M., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 (2001).
43. Loh, M. L., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103, 2325-2331 (2004).
44. Tartaglia, M., et al. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br. J. Haematol. 129, 333-339 (2005).
45. Loh, M. L., et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Childrens Cancer Group. Leukemia 18, 1831-1834 (2004).
46. Tartaglia, M., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34, 148-150 (2003).
47. Yamamoto, T., et al. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk. Res. 30, 1085-1089 (2006).
48. Aceto, N., et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med. 18, 529-537 (2012).
49. Rankin, J., Short, J., Turnpenny, P., Castle, B. & Hanemann, C. O. Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. Am. J. Med. Genet. A 161A, 2027-2029 (2013).
50. Bentires-Alj, M., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64, 8816-8820 (2004).
51. Cotton, J. L. & Williams, R. G. Noonan syndrome and neuroblastoma. Arch. Pediatr. Adolesc. Med. 149, 1280-1281 (1995).
52. Lopez-Miranda, B., Westra, S. J., Yazdani, S. & Boechat, M. I. Noonan syndrome associated with neuroblastoma: a case report. Pediatr. Radiol. 27, 324-326 (1997).
53. Martinelli, S., et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet. Cytogenet. 166, 124-129 (2006).
54. Miyamoto, D., et al. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27, 3508-3515 (2008).
55. Sturla, L. M., et al. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br. J. Cancer 105, 1235-1243 (2011).
56. Janzarik, W. G., et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 38, 61-63 (2007).
57. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
58. Liu, K. W., et al. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J. Clin. Invest. 121, 905-917 (2011).
59. Feng, H., et al. Dynamin 2 mediates PDGFRalpha-SHP-2-promoted glioblastoma growth and invasion. Oncogene 31, 2691-2702 (2012).
60. Zhan, Y., Counelis, G. J. & O'Rourke, D. M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp. Cell Res. 315, 2343-2357 (2009).
61. Wei, J., et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clinical Cancer Res. 16, 461-473 (2010).
62. Chung, C., et al. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy. Int. J. Radiat Oncol. Biol. Phys. 85, 805-812 (2013).
63. Ohh, M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2, 423-427 (2000).